Heavy menstrual bleeding: work-up and management.
Level 5 - mechanism / opinion, no new human data
Narrative educational review without systematic search or quantitative data synthesis
PubMed 27913486 · doi:10.1182/asheducation-2016.1.236
What was done
This educational narrative review outlined the clinical presentation, diagnostic evaluation, and treatment strategies for heavy menstrual bleeding (HMB), with a focus on identifying underlying bleeding disorders and managing patients on anticoagulation therapy.
What was found
The author reported that HMB affects ~90% of women with underlying bleeding disorders and ~70% of women receiving anticoagulation. HMB can be clinically predicted by blood clots ≥1 inch in diameter, low ferritin, and "flooding" (requiring pad/tampon changes more frequently than hourly). Work-up centers on identifying uterine or endometrial causes, ovulatory disorders, or coagulopathies. Treatment choices depend on etiology, patient age, and fertility goals, with hemostatic therapy offering an alternative to hormonal or surgical interventions.
Why it matters
It highlights clinical indicators that should prompt hematology referral in women presenting with severe menorrhagia and frames hemostatic therapy as a key treatment pathway alongside standard gynecologic options.
Limits
As an educational review, it presents expert narrative synthesis rather than a systematic review or primary trial data. The abstract provides estimated proportions without primary source sample sizes, confidence intervals, or diagnostic accuracy metrics.
Cited by
- supports Menstrual blood clots that are the size of a quarter or larger are considered abnormal and indicative of excessive bleeding, whereas dime-sized clots can be within the normal physiological range.